会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 31. 发明授权
    • Implantable cardiac device for monitoring diastolic heart failure and method of operation and use thereof
    • 用于监测舒张性心力衰竭的可植入心脏装置及其操作和使用方法
    • US07526338B1
    • 2009-04-28
    • US11136268
    • 2005-05-23
    • Jong GillXiaoyi MinGene A. Bornzin
    • Jong GillXiaoyi MinGene A. Bornzin
    • A61N1/365A61B5/02
    • A61B5/0215A61N1/3627A61N1/365A61N1/36564G06F19/3481G16H50/50
    • An implantable cardiac device is used to measure one or more parameters relating to cardiac activity of a patient's heart, from which diastolic heart failure (“DHF”) may be monitored and/or detected. These parameters are used to calculate ventricular isovolumetric relaxation time or a related time value. Heart conditions possibly having an influence on the ventricular isovolumetric relaxation time, other than heart conditions due to reduced compliance, may be detected and used to prevent an incorrect calculation of the ventricular isovolumetric relaxation time. The parameters may be measured and the relaxation time calculated multiple times over a period of time, which enables monitoring of the progression of change in the relaxation time. The relaxation time and the progression of change therein are indicators of DHF.
    • 可植入心脏装置用于测量与患者心脏的心脏活动相关的一个或多个参数,可以从该心脏的心脏监测和/或检测舒张性心力衰竭(“DHF”)。 这些参数用于计算心室等容弛豫时间或相关时间值。 可能检测并用于可能对心室等容舒张时间(由于依从性降低而导致的心脏状况)影响的心脏状况,以防止心室等容性弛豫时间的错误计算。 可以测量参数并且在一段时间内多次计算松弛时间,这可以监测松弛时间的变化进展。 舒缓时间及其变化的进展情况是DHF的指标。
    • 34. 发明授权
    • Detection of renal failure by cardiac implantable medical device
    • 通过心脏植入式医疗器械检测肾功能衰竭
    • US07400920B1
    • 2008-07-15
    • US11202553
    • 2005-08-11
    • Jong GillGene A. Bornzin
    • Jong GillGene A. Bornzin
    • A61B5/04
    • A61B5/0468A61B5/201
    • Morphological features within electrical cardiac signals are tracked and changes in features are monitored to detect renal failure. The morphological feature may be an interval between corresponding polarization events such as the interval between QRS-complexes and peaks of corresponding T-waves (QTmax interval); the interval between QRS-complexes and ends of corresponding T-waves (QTend interval); or the interval between P-waves and corresponding QRS-complexes (PR interval). The feature may also be the elevation of a cardiac signal segment between corresponding polarization events, such as QRS-complexes and corresponding T-waves (ST segment); a duration of a polarization event, such as a QRS-complex (QRS width); or an amplitude of a polarization event, such as a T-wave (T-wave amplitude). The change in the feature may comprise a decrease in QTmax intervals, a decrease in QTend intervals, a deviation in ST segment elevation, an increase in QRS width, an increase in PR interval or a deviation in T-wave amplitude.
    • 跟踪电心电信号中的形态学特征,监测特征变化以检测肾功能衰竭。 形态特征可以是相应的极化事件之间的间隔,例如QRS-复合物之间的间隔和对应的T波的峰值(QTmax间隔); QRS复合体与相应T波结束之间的间隔(QTend间隔); 或P波与相应的QRS复合体之间的间隔(PR间隔)。 该特征还可以是对应的极化事件之间的心脏信号段的升高,例如QRS复合物和相应的T波(ST段); 极化事件的持续时间,例如QRS复合(QRS宽度); 或极化事件的振幅,例如T波(T波振幅)。 特征的变化可以包括QTmax间隔的减小,QTend间隔的减小,ST段抬高的偏差,QRS宽度的增加,PR间期的增加或T波幅度的偏差。